Virtual Library

Start Your Search

Peixin Chen



Author of

  • +

    P47 - Small Cell Lung Cancer/NET - Biology / Translational (ID 234)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 2
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P47.07 - Exploration of Aberrant Methylation Patterns in the Chemotherapy Insensitivity of Small Cell Lung Cancer (ID 3234)

      00:00 - 00:00  |  Presenting Author(s): Peixin Chen

      • Abstract
      • Slides

      Introduction

      Epigenetic alterations of specific genes are closely related to chemotherapeutic efficacy in various cancers. However, few comprehensive profiles of differentially methylated genes (DMGs) in small cell lung cancer (SCLC) were available.

      Methods

      In the study, Methylated DNA immunoprecipitation sequencing and RNA sequencing was employed to clinical small cell lung cancer (SCLC) patients. Then, we verified the therapeutic predictive effects of differentially methylated genes (DMGs) in 62 SCLC cell lines.

      Results

      Of 4552 DMGs which were selected (fold change ≥ 2, p<0.01) between chemo-sensitive and chemo-insensitive group, coding genes constituted the largest percentage (3873/4551, 85.08%), followed by lncRNAs (479/4551, 10.52%) and miRNAs (162/4552, 3.56%). Further, both two groups demonstrated two methylation peaks near transcription start site and transcription end site. Two lncRNA-miRNA-mRNA networks which based on genes that showed opposite results in genetic expression and epigenetic modifications suggested the extensive genome connection between chemotherapy efficacy-related non-coding RNAs (ncRNAs) and mRNAs (Figure 1). Combing four DMGs, including hsa-miR-34a, LINC00461, LINC01018, and LINC01484 could effectively predict first-line chemotherapy response in SCLC, indicating that they might play vital roles in SCLC chemotherapy insensitivity (Figure 2).

      figure 1.pngfigure2.png

      Conclusion

      In SCLC, multiple efficacy-related ncRNAs and mRNAs were modified by methylation. In addition, DMGs identified in our research might be served as predictors for chemotherapy effect and promising therapeutic targets to reverse drugs-insensitivity in SCLC. Further comprehensive studies of these findings are worthy of expecting.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P47.13 - Galectin-9, A Novel Prognostic Factor in Small Cell Lung Cancer (ID 1232)

      00:00 - 00:00  |  Presenting Author(s): Peixin Chen

      • Abstract
      • Slides

      Introduction

      For small cell lung cancer (SCLC) therapy, immunotherapy might have unique advantages to some extent. Galectin-9 (Gal-9) palys an important role in anti-tumor immunity, while little is known of its function in SCLC.

      Methods

      By mean of immunohistochemistry (IHC), we tested the expression level of Gal-9 and other immune markers on both tumor cells and tumor-infiltrating lymphocytes (TILs) in 102 surgical-resected early stage SCLC clinical samples. On the basis of statistical analysis and machine learning results, the Gal-9-based immune risk score model was constructed and its predictive performance was evaluated. Then, we thoroughly explored the effects of Gal-9 and immune risk score on SCLC immune microenvironment and immune infiltration in different cohorts and platforms.

      Results

      In the SCLC cohort for IHC, the expression level of Gal-9 on TILs was statistically correlated with the levels of PD-1 (p=0.001), PD-L1 (p<0.001), CD3 (p<0.001), CD4 (p<0.001), CD8 (p<0.001), and FOXP3 (p=0.047). High Gal-9 protein expression on TILs indicated better recurrence-free survival (Figure 1;p=0.009). The immune risk score model which consisted of Gal-9 on TILs, CD4, and PD-L1 on TILs was established and validated so as to differentiate high- or low-risk SCLC patients. The prognostic predictive performance of immune risk score model was better than single immune biomarker (AUC 0.671 vs. 0.621-0.644). High Gal-9-related enrichment pathways in SCLC were enriched in immune system diseases and rheumatic disease. Furthermore, we found that SCLC patients with low immune risk score presented higher fractions of activated memory CD4 T cells than it of the high immune risk score cohort (Figure 2; p=0.048).

      1.png

      figure 2.png

      Conclusion

      Gal-9 is markedly related to tumor immune microenvironment and immune infiltration in SCLC. This study emphasized the predictive value and promising clinical applications of Gal-9 in SCLC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.